Status:
NOT_YET_RECRUITING
A Prospective muLticEnter Registry in chrONic coronARy synDrOme
Lead Sponsor:
University of Roma La Sapienza
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Brief Summary
In patients with chronic coronary syndrome (CCS), clopidogrel has a class I/A indication in patients undergoing elective percutaneous coronary intervention (PCI). Although unproven, the possibility ex...
Detailed Description
In patients with chronic coronary syndrome (CCS), clopidogrel has a class I/A indication in patients undergoing elective percutaneous coronary intervention (PCI) (Figure 1). Initiation of oral P2Y12 i...
Eligibility Criteria
Inclusion
- Patients with CCS undergoing elective PCI
- Patients' written informed and privacy consent obtained before the PCI procedure
- Male or female patients 18 to 80 years old
- Assessment of response to anti-platelet agents by VerifyNowTM
Exclusion
- Patients with active bleeding
- Patients with hypersensitivity to any anti-platelet agents or to any of its excipients
- Known pregnancy or breast-feeding female patients
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06198673
Start Date
January 1 2024
End Date
December 31 2026
Last Update
January 10 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.